$LEXX News
Last published 1w ago
- 1w agoLEXXLexaria Enters a New Pharmaceutical Agreement for DehydraTECHACCESS NewswireThird pharmaceutical company relationship entered KELOWNA, BC / ACCESS Newswire / November 4, 2026 / Lexaria Bioscience Corp. , a global innovator in drug
- 2w agoLEXXLexaria Celebrates its 70th Patent AwardACCESS NewswireNew patents awarded in the US, Canada, and EuropeIP protection for treatments for Epilepsy, Diabetes, and Hypertension KELOWNA, BC / ACCESS Newswire / October 28, 2026 / Lexaria Bioscience Corp. (the
- 3w agoLEXXLexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on ScheduleACCESS NewswireKELOWNA, BC / ACCESS Newswire / October 21, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, reports that full enrollment has
- 3w agoLEXXLexaria Announces Results from Animal Study GLP-1-A26-1ACCESS NewswireResults highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (the "Company" or
- 1mo agoLEXXGLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral MedicationsACCESS NewswireOral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS Newswire /
- 1mo agoLEXXLexaria Updates Financial PositionACCESS NewswireKELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms is providing the following
- 2mo agoLEXXLexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross ProceedsACCESS NewswireKELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, today closed its previously
- 2mo agoLEXXLexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross ProceedsACCESS NewswireKELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, today announced the
- 2mo agoLEXXLexaria to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceACCESS NewswireKELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. , a global innovator in oral drug delivery platforms, announces that it will
- 2mo agoLEXXLexaria Receives USD$2.6 Million Tax Rebate PaymentACCESS NewswireLexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. ,
- 2mo agoLEXXDehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2ACCESS NewswireProprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry studyProprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug
- 3mo agoLEXXLexaria Enters a Material Transfer Agreement With PegBioACCESS NewswireKELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, announces that it has entered into a
- 3mo agoLEXXLexaria Announces Effective Date for Reverse Stock SplitACCESS NewswireKELOWNA, BC / ACCESS Newswire / July 30, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, announces that it intends to effect a
- 4mo agoLEXXLexaria Updates Business DevelopmentACCESS NewswireKELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, is pleased to have experienced many
- 4mo agoLEXXLexaria's Human Study GLP-1-H26-7 Has Begun Dosing on ScheduleACCESS NewswireKELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, announces that dosing began on schedule
- 4mo agoLEXXLexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on ScheduleACCESS NewswirePotentially Valuable Novel Compositions Being InvestigatedLexaria Also Receives Additional New Granted Patent KELOWNA, BC / ACCESS Newswire / June 23, 2026 / Lexaria Bioscience Corp. (the
- 4mo agoLEXXGLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to ExpandACCESS NewswireMore People Than Ever Taking GLP-1 Drugs for Weight LossGrowing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (the
- 5mo agoLEXXLexaria's Animal Study Examining Next-Generation GLP-1 drugs is UnderwayACCESS NewswireRetatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH™ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. ("Lexaria" or the
- 5mo agoLEXXLexaria Attending the BIO International Convention, as Part of a Broader Business Development ProgramACCESS NewswireKELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. , a global innovator in oral drug delivery platforms, announces that it is attending the BIO International
- 5mo agoLEXXLexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7ACCESS NewswireKELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. , a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been
- 6mo agoLEXXLexaria Bioscience Releases Second Episode of Investor Video SeriesACCESS NewswireCEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities KELOWNA, BC / ACCESS Newswire / May 7, 2026 / Lexaria Bioscience Corp. ("Lexaria" or the
- 6mo agoLEXXLexaria Updates Progress on Human Study #7ACCESS NewswireKELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. , a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7
- 6mo agoLEXXLexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder CommunicationsACCESS NewswireInaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. ("Lexaria" or
- 6mo agoLEXXMaterial Transfer Agreement Between Pharmaceutical Company and Lexaria is ExtendedACCESS NewswireKELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. , a global innovator in oral drug delivery platforms, provides this update on the Material Transfer
- 6mo agoLEXXLexaria Launches New Study to Examine Next-Generation GLP-1 DrugsACCESS NewswireContracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. , (the
- 6mo agoLEXXLexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry SalesACCESS Newswire600,000 New Wegovy® Pill Prescriptions Written in First Two Months KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. , , a global innovator in drug
- 7mo agoLEXXLexaria's New Animal Study Aims to Expand Valuable Intellectual PropertyACCESS NewswireContracts signed for Animal Study GLP-1-A26-1KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. , , a global innovator in drug delivery platforms, is
- 7mo agoLEXXLexaria Applauds Eli Lilly's Foundayo(TM) Drug ApprovalACCESS NewswireThe number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effectsKELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. , (the
- 7mo agoLEXXLexaria to Begin New Human Clinical Study in GLP-1ACCESS NewswireContracts signed for Human Pilot Study #7 KELOWNA, BC / ACCESS Newswire / April 1, 2026 / Lexaria Bioscience Corp. , , a global innovator in drug delivery platforms
- 7mo agoLEXXLexaria's Robust Patent Portfolio Continues to GrowACCESS NewswireLexaria receives 5 new patents including 2 for diabetes treatment utilizing GLP-1 drugsKELOWNA, BC / ACCESS Newswire / March 26, 2026 / Lexaria Bioscience Corp. , , a global
- 7mo agoLEXXLexaria's Oral GLP-1 Drug Strategy Validated by IndustryACCESS Newswire"The window to shape the oral GLP-1 market is open now...."Early-stage discussions with several multinational pharmaceutical companies currently underwayKELOWNA, BC / ACCESS Newswire / March 24, 2026 / Lexaria Bioscience
- 8mo agoLEXXLexaria Announces New R&D Plans for 2026ACCESS NewswireExciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. , , a global innovator in
- 9mo agoLEXXLexaria Announces Positive Final Results From Human Pilot Study #5ACCESS NewswireCompany Further Examining the Pursuit of the World's First Oral Liraglutide ProductKELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. , , a global
- 9mo agoLEXXNAGEPMWSTTHE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke PointGlobeNewswireVANCOUVER, British Columbia, Jan. 21, 2026 (GLOBE NEWSWIRE) -- USA News Group - News Commentary – The $6.16 trillion health market is hitting a wall as consumers dump generic stimulants for $57.1 billion in precision
- 10mo agoLEXXLexaria Releases Annual Letter from the CEOACCESS NewswireKELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. , , a global innovator in drug delivery platforms is pleased to provide this Annual
- 10mo agoLEXXLexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4ACCESS NewswireKELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, provides the following additional
- 10mo agoLEXXPrimary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4ACCESS NewswireDehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®Recent financings create runway
- 11mo agoLEXXLexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesACCESS NewswireKELOWNA, BC / ACCESS Newswire / December 16, 2025 / Lexaria Bioscience Corp. ) , a global innovator in drug delivery platforms, today announced the closing of its
- 11mo agoLEXXLexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesACCESS NewswireKELOWNA, BC / ACCESS Newswire / December 15, 2025 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, today announced that it has entered into a
- 12mo agoLEXXMaterial Transfer Agreement Between Pharmaceutical Company and Lexaria is ExtendedACCESS NewswireKELOWNA, BC / ACCESS Newswire / November 12, 2025 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, provides this
- 1y agoLEXXLexaria Bioscience Corp. Provides Strategic UpdateACCESS NewswireStrategic Business Development Advisory Firm Engaged To Support New Business Development ActivitiesLexaria Awarded 4 New Patents KELOWNA, BC / ACCESS Newswire / October 9, 2025 / Lexaria Bioscience Corp.
- 1y agoLEXXLexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesACCESS NewswireKELOWNA, BC / ACCESS Newswire / September 29, 2025 / Lexaria Bioscience Corp.
- 1y agoLEXXLexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesACCESS NewswireKELOWNA, BC / ACCESS Newswire / September 26, 2025 / Lexaria Bioscience Corp. ) , a global innovator in drug delivery platforms, today announced that it
- 1y agoLEXXLexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in BrainACCESS NewswireEnhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy KELOWNA, BC / ACCESS Newswire / September 19, 2025 / Lexaria Bioscience Corp. (the
- 1y agoLEXXLexaria Attending the 27th Annual H.C. Wainwright Global Investment ConferenceACCESS NewswireKELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, today announced that
- 1y agoLEXXLexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" MilestoneACCESS NewswireKELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms, is pleased to
- 1y agoLEXXGLP-1 "Arms Race" Broadens to Include Dozens of CompaniesACCESS NewswireLexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (the "Company" or
- 1y agoLEXXLexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 StudyACCESS NewswireDehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 study arms
- 1y agoLEXXLexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-IndustryACCESS NewswireThe fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
- 1y agoLEXXLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideACCESS NewswireNew patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (the "Company"